Mahesh Amin
Cardiovascular Disease · Clearwater, FLNPI 1013985043
Payments from drug & device makers
Across 157 payments — averaging $361.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$44K
- AstraZeneca$4K
- Medtronic$4K
- Pfizer$3K
- Abbott$377
- Amgen$366
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$7,33054%
- Grants$290%
- Travel & lodging$1,2439%
- Food & beverage$4,98737%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $43,954 |
| AstraZeneca | 15 | $4,295 |
| Medtronic(2 entities) | 39 | $3,517 |
| Pfizer | 12 | $3,008 |
| Abbott | 5 | $377 |
| Amgen | 20 | $366 |
| Johnson & Johnson | 12 | $191 |
| Boston Scientific | 1 | $191 |
| Impulse Dynamics (USA) Inc. | 1 | $159 |
| Boehringer Ingelheim | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $108 |
| Sanofi-aventis U.S. LLC | 4 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $59 |
| Chiesi USA, Inc. | 4 | $48 |
| Nuwellis, Inc. | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Cook Medical LLC | 1 | $29 |
| Inari Medical, Inc. | 1 | $29 |
| Novo Nordisk | 2 | $26 |
| GE HealthCare | 1 | $22 |
| Infobionic, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$4,697
- ELIQUIS$2,850
- OPTIMIZER$319
- Farapulse$191
- Xience Sierra Coronary Stent System$177
- COREVALVE EVOLUT R$166
- Adapta$125
- Claria MRI$118
- Proclaim Family of SCS IPGs$106
- BRILINTA$105
How this compares
$56,753 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 19 | $18,253 |
| Rosuvastatin Calcium | 16 | $207 |
| Lisinopril | 20 | $140 |
| Spironolactone | 11 | $121 |
| Amlodipine Besylate | 15 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $191 | $18,25319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Clearwater
- Jorge NavasClearwater$1.6M
- Jason ZelenkaClearwater$1.3M
- Jay AminClearwater$851K
- Marilyn KingClearwater$674K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.